Drug Shortage Report for VISIPAQUE 270

Last updated on 2023-01-05 History
Report ID 161439
Drug Identification Number 02145766
Brand name VISIPAQUE 270
Common or Proper name iodixanol injection USP
Company Name GE HEALTHCARE CANADA INC
Market Status MARKETED
Active Ingredient(s) IODIXANOL
Strength(s) 550MG
Dosage form(s) SOLUTION
Route of administration INTRAVENOUS INTRA-ARTERIAL INTRA-ARTERIAL INTRAVENOUS
Packaging size 50 mL
ATC code V08AB
ATC description X-RAY CONTRAST MEDIA, IODINATED
Reason for shortage Other (Please describe in comments)
Anticipated start date 2022-07-01
Actual start date 2022-06-02
Estimated end date 2023-03-31
Actual end date 2023-01-04
Shortage status Resolved
Updated date 2023-01-05
Company comments Covid Related Shutdown in China. This is a fluid situation that we are working through daily. We will keep all customers informed on what orders to expect during this period so they can plan accordingly.
Health Canada comments Canadian Association of Radiologists: Statement on Iodinated Contrast Media Shortage - https://car.ca/news/statement-on-iodinated-contrast-media-shortage/
Tier 3 Status No
Contact Address 1919 MINNESOTA COURT
MISSISSAUGA, ONTARIO
CANADA L5N 0C9
Company contact information 800-387-7146 canadainfo@ge.com

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v16 2023-01-05 English Compare
v15 2023-01-04 French Compare
v14 2023-01-04 English Compare
v13 2023-01-04 French Compare
v12 2023-01-04 English Compare
v11 2022-09-20 French Compare
v10 2022-09-20 English Compare
v9 2022-07-05 French Compare
v8 2022-07-05 English Compare
v7 2022-06-03 English Compare
v6 2022-06-02 French Compare
v5 2022-06-02 English Compare
v4 2022-06-01 French Compare
v3 2022-06-01 English Compare
v2 2022-05-27 French Compare
v1 2022-05-27 English Compare

Showing 1 to 16 of 16